A novel substitution of proline (P32L) destabilises β2-microglobulin inducing hereditary systemic amyloidosis.


Journal

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
ISSN: 1744-2818
Titre abrégé: Amyloid
Pays: England
ID NLM: 9433802

Informations de publication

Date de publication:
Dec 2022
Historique:
pubmed: 17 5 2022
medline: 3 1 2023
entrez: 16 5 2022
Statut: ppublish

Résumé

β2-microglobulin amyloidosis was first described in the 1980s as a protein deposition disease associated with long-term haemodialysis. More recently, two inherited forms resulting from separate point mutations in the β2-microglobulin gene have been identified. In this report, we detail a novel β2M variant, P32L, caused by a unique dinucleotide mutation that is linked to systemic hereditary β2-microglobulin amyloidosis. Three family members from a Portuguese kinship featured cardiomyopathy, requiring organ transplantation in one case, along with soft tissue involvement; other involvements included gastrointestinal, neuropathic and sicca syndrome. The P32L variant was caused by the unique heterozygous dinucleotide mutation c.154_155delinsTT. Amyloid disease featured lowered serum β2-microglobulin levels with near equal amounts of circulating P32L and wild-type proteins; amyloid deposits were composed exclusively of P32L variant protein. This work provides both clinical and experimental evidence supporting the critical role of P32 residue replacement in β2M amyloid fibrillogenesis.

Sections du résumé

BACKGROUND UNASSIGNED
β2-microglobulin amyloidosis was first described in the 1980s as a protein deposition disease associated with long-term haemodialysis. More recently, two inherited forms resulting from separate point mutations in the β2-microglobulin gene have been identified. In this report, we detail a novel β2M variant, P32L, caused by a unique dinucleotide mutation that is linked to systemic hereditary β2-microglobulin amyloidosis.
METHODS UNASSIGNED
Three family members from a Portuguese kinship featured cardiomyopathy, requiring organ transplantation in one case, along with soft tissue involvement; other involvements included gastrointestinal, neuropathic and sicca syndrome.
RESULTS UNASSIGNED
The P32L variant was caused by the unique heterozygous dinucleotide mutation c.154_155delinsTT. Amyloid disease featured lowered serum β2-microglobulin levels with near equal amounts of circulating P32L and wild-type proteins; amyloid deposits were composed exclusively of P32L variant protein.
CONCLUSIONS UNASSIGNED
This work provides both clinical and experimental evidence supporting the critical role of P32 residue replacement in β2M amyloid fibrillogenesis.

Identifiants

pubmed: 35575118
doi: 10.1080/13506129.2022.2072199
doi:

Substances chimiques

Amyloid 0
beta 2-Microglobulin 0
Proline 9DLQ4CIU6V

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

255-262

Auteurs

Tatiana Prokaeva (T)

Amyloidosis Center, Boston University School of Medicine, Boston, MA, USA.

Tracy Joshi (T)

Amyloidosis Center, Boston University School of Medicine, Boston, MA, USA.

Elena S Klimtchuk (ES)

Amyloidosis Center, Boston University School of Medicine, Boston, MA, USA.

Victoria M Gibson (VM)

Amyloidosis Center, Boston University School of Medicine, Boston, MA, USA.

Brian Spencer (B)

Amyloidosis Center, Boston University School of Medicine, Boston, MA, USA.

Omar Siddiqi (O)

Amyloidosis Center, Boston University School of Medicine, Boston, MA, USA.

Dobrin Nedelkov (D)

Isoformix Inc., Phoenix, AZ, USA.

Yueming Hu (Y)

Isoformix Inc., Phoenix, AZ, USA.

John L Berk (JL)

Amyloidosis Center, Boston University School of Medicine, Boston, MA, USA.

Sarah A M Cuddy (SAM)

Amyloidosis Program, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.

Surendra Dasari (S)

Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.

April Chiu (A)

Department of Laboratory of Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.

Lauren A Choate (LA)

Department of Laboratory of Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.

Ellen D McPhail (ED)

Department of Laboratory of Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.

Haili Cui (H)

Amyloidosis Center, Boston University School of Medicine, Boston, MA, USA.
Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA, USA.

Hui Chen (H)

Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA, USA.

Eric J Burks (EJ)

Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA, USA.

Vaishali Sanchorawala (V)

Amyloidosis Center, Boston University School of Medicine, Boston, MA, USA.

Lawreen H Connors (LH)

Amyloidosis Center, Boston University School of Medicine, Boston, MA, USA.
Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH